BRAF or ERBB2. Low-grade serous ovarian carcinoma (LGSOC) accounts for less then 5% of all ovarian 48 serous carcinomas, other epithelial ovarian cancer types are endometrioid (8-10%), clear cell (8%), 49 seromucinous (3%), mucinous (3%) and Brenner (1%) tumors (3). LGSOC is characterized by mutations 50 of the KRAS, BRAF or ERBB2 genes, in which approximately two thirds of tumors have a mutually 51 exclusive mutation in one of these genes (4). KRAS, BRAF and ERBB2 are upstream activators of the 52 mitogen-activated protein kinase (MAPK) pathway, leading to cellular proliferation. As both types of 53 cancer are associated with vague symptoms in early stages, the majority of patients present with 54 advanced-stage disease (5) . The presence of peritoneal carcinomatosis, which results from intra-55 abdominal metastases, is associated with the late presentation of the disease. Treatment difficulties 56 of peritoneal metastases and the possible recurrences do both contribute to a poor prognosis of this 57 cancer (6). Given the high relapse rate and poor prognosis of this disease, interest increases in the 58 development of new treatment approaches (7) . Therapeutic management of ovarian cancer has 59 traditionally been based on a combination of surgery and platinum-/taxane-based chemotherapy (6). 60
However, LGSOC is not as responsive to platinum-/taxane-based chemotherapy as HGSOC. Although a 61 clear involvement of the MAPK pathway in the disease is demonstrated, a phase 3 study using the MEK 62 inhibitor binimetinib showed mid-term discontinuation, most probably due to escape mechanisms 63 leading to lack of treatment efficacy (8). 64
In every aspect of translational cancer research, from the biological aspects of the disease to the 65 development of new treatments, the use of preclinical models is a key component. In recent years, 66 there has been an increasing interest in the application of organoids and patient-derived xenografts 67 (PDXs) because of their high potential as an essential tool for personalized medicine (9) (10) (11) . The process 68 of generating PDXs (also known as tumorgraft models) is based on the transfer of fresh tumor tissue 69 (primary or metastatic) from the patient directly to an immunocompromised mouse (12) . 70
Depending on the cancer type, pretreatment, amount of tissue available, molecular properties etc., 71 the success rate of the PDX will vary (13). The organ environment can affect tumor engraftment, 72 highlighting the role of the site of implantation. Traditionally the tumor fragment is implanted into an 73 area unrelated to the original tumor site, which is considered a heterotopic implantation (generally 74 subcutaneous). On the other hand, tumor xenografts can also grow orthotopically into the 75 corresponding anatomic region but their use is often hindered by a need for a high level of technical 76 skills, time and cost (14). For some cancers, such as colorectal, breast, lung, pancreatic, head and neck, 77 melanoma, gastric, ovarian, prostate and renal cancer, methodologies for PDX establishment and 78 characterization are already described in literature with engraftment rates ranging from 9 to 90% of 79 success (13, 15) . 80
In this work, for the first time, an orthotopic PDX model, based on a subperitoneal tumor slurry 81 injection, and cancer cell line from a peritoneal metastasis of LGSOC were established. This model 82 showed a KRAS mutation and sensitivity to the MEK inhibitor trametinib demonstrating its clinical 83 relevance to study treatment responsiveness and resistance mechanisms. 84
Methods

85
Establishment of peritoneal metastasis (PM)-PDX models 86
Fresh peritoneal tissue specimens from 10 consenting patients with metastatic serous epithelial 87 ovarian cancer (FIGO stage III or IV) were collected at the time of debulking surgery at Ghent University 88 Hospital, Belgium. Nine patients were diagnosed with HGSOC and one with LGSOC. The study protocol 89 was approved by the institutional review board of the Ghent University Hospital and the trial is 90 registered as ClinicalTrial.gov NCT02567253 with EudraCT number 2015-000418-23. Samples were 91 processed to a tumor slurry and injected in SCID/Beige mice within 75 minutes after removal from the 92 patient. Tumors were minced in limiting volumes of RPMI 1640 media (Life Technologies, Ghent, 93 Belgium), supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin (Life Technologies, 94 Ghent, Belgium). After a centrifugation step at 1500×g for 3 minutes, the upper culture medium was 95 removed and tumor tissue was suspended in 1:1 Matrigel (Corning, The Netherlands). Further, a 96 laparotomy was performed and 50 µL of the tumor suspension using a 19G needle was injected 97 bilateral subperitoneally in three female 4 to 5 week old SCID/Beige (C.B-17/IcrHsd-Prkdc scid Lyst bg-J ) 98 mice (Envigo, The Netherlands). Animal studies were conducted in accordance with the local 99 committee on the Ethics of Animal Experiments (Ghent University Hospital, Ghent, Belgium [ECD 100 15/28]). Cryopreserved tumors were minced and stored 1:1 in freezing media (90% FBS/10% DMSO) 101 at -80°C and then in liquid nitrogen indefinitely. 102
Tissue processing and immunohistochemistry 103
Tissues collected from mice or patients were fixed overnight in neutral buffered 10% formalin solution 104 (Sigma-Aldrich, Belgium) and processed in the lab (H&E staining) or in the tissue core facility at Ghent 105 University Hospital (immunohistochemistry). 106 107 108
In vivo imaging 109
Transparent ultrasound transmission Polaris II gel (Ondes & Rayons Medical, France) was applied to 110 bare skin and a MicroScan™ MS550D (22-55 MHz, VisualSonics Inc., Canada) transducer with the 111 Vevo® 2100 imaging system (VisualSonics Inc., Canada) was used to analyse the tumor cross-sectional 112 area in Vevo LAB 1.7.1 (VisualSonics Inc., Canada). 113
Establishment of tumor-derived cell lines 114
To establish cell lines derived from the peritoneal metastasis and a PM-PDX-model, tumor samples 115 were cut into pieces of 2-4 mm and suspended using the tumor dissociation protocol with the 116 GentleMacs® dissociator (Miltenyi Biotec GmbH, Germany). The cell suspension was applied to a cell 117 strainer (70 µm, Corning, The Netherlands), centrifuged at 300×g for 7 minutes and after aspiration of 118 the supernatant resuspended in complete EMEM supplemented with 10% fetal bovine serum, 100 119 U/ml penicillin and 100 µg/ml streptomycin (Life Technologies, Ghent, Belgium). The first weeks, cells 120 were maintained in a 6-well plate (Novolab, Belgium) before culturing in a T25 falcon at 37°C and 5% 121 CO2 in air. The cell culture was monthly tested for Mycoplasma by using MycoAlert Plus Kit (Lonza, 122 Basel, Switzerland). 123
KRAS mutation analysis 124
Exons 2, 3 and 4 of the KRAS, NRAS and HRAS genes and exon 15 of the BRAF gene were analysed using 125 a PCR-based enrichment strategy followed by library preparation and MiSeq sequencing. In brief, DNA 126 was extracted using the QIAamp DNA Blood mini kit (Qiagen) for cell culture samples or using the 127 QIAamp DNA FFPE Tissue kit and deparaffinisation solution (Qiagen) for formalin-fixed paraffin-128 embedded (FFPE) slices. The DNA concentration was measured by use of the Trinean Dropsense96 129 UV/VIS droplet reader (Trinean) or with Qubit (Thermofisher). For the PCR, the KAPA2G Robust 130 mastermix was used together with 0.5 µM primers and 10 ng of DNA template in a 30 µl reaction 131 volume. The PCR protocol consists of 5 min at 95°C, 50 cycles (30 sec at 95°C, 45 sec at 60°C and 45 sec 132 at 72°C) and 1 min at 72°C. Library preparation made use of the Nextera XT kit (Illumina) and massive 7 parallel sequencing was performed on MiSeq (Illumina) (16). All PCR and massive parallel sequencing 134 reactions were performed in duplicate. Data-analysis was performed by use of the commercial 135 software package CLC bio Genomics Workbench v9 (Qiagen). replaced by pLenti6-LUC2CP-EGFP-Blast virus containing medium for 24 hours. Cells expressing the 145 construct were selected after addition of 2.5 µg/ml Blasticidin S (R21001, ThermoFisher) to the 146 medium. After 10 days the cells expressing the LUC2CP-EGFP fusion protein were sorted with the BD 147 FACSAria III cell sorter. 148
Clonogenic assay 149
500 PM-PDX-derived cells were seeded in different T25 cell culture flasks and immediately treated with 150 15, 150 or 1500 pg/ml estrogen or 1, 10 or 100 nM trametinib, selumetinib or fulvestrant. Control 151 conditions were 0.1% DMSO or stripped medium for the estrogen experiment. Cells were incubated 152 during 8 days in the presence of the drug (3 T25 flasks/condition) and effectiveness of all agents was 153 determined by staining the colonies using crystal violet as an endpoint measurement. 154
IncuCyte ZOOM monitored studies 155
Real-time monitoring of cell confluency was performed using the IncuCyte ZOOM System (Essen 156
Bioscience, Hertfordshire, UK) according to the manufacturer's guidelines. For cell confluency 157 monitoring, cells were seeded in 96-well clear-bottom Corning® Costar® cell culture plates at 2 000 cells per well (100 µl/well) and allowed to adhere 24 hours at 37°C and 5% CO2 in air. Subsequently, 159 cells were exposed to the drugs in complete EMEM medium and microscopic images (4 images/well) 160 were taken every two hours for the duration of the experiment. All images were analysed and cell 161 confluency was deduced using IncuCyte software. Each condition was performed in, at least, four fold. 162
Chemotaxis cell migration was studied for SK-OV-3 luc IP1 and PM-LGSOC-01 cells using the IncuCyte™ 163
ClearView 96-Well Cell Migration plate coated with 1% Matrigel (Corning, The Netherlands) in 0% FBS 164 EMEM medium. 3 000 cells/well were seeded (60 µL volume) with 0.1% FBS to the top and 200 µL 10% 165 FBS to the bottom. Cell migration was followed using the phase contrast cell confluency monitoring. 166
Cell lysates and western blotting 167
Proteins were extracted from the cells using the Laemmli lysis buffer (0.125 M Tris-HCl, 10% glycerol, 168 2.3% sodium dodecyl sulfate (SDS), pH 6.8). After an ultrasonication step, cell lysates were suspended 169 in reducing sample buffer (1 M Tris-HCl, 30% glycerol, 6% SDS, 3% β-mercaptoethanol, 0.005% 170 bromophenol blue, pH 6.8) and boiled for 5 minutes at 95°C. 20 µg proteins of the cell line were 171 exposed to a 10% SDS-PAGE gel and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA, 172 USA). After blocking the membranes using 5% non-fat milk or bovine serum albumin (BSA) in 173 phosphate-buffered saline (PBS) with 0.5% Tween 20 (Sigma-Aldrich, Belgium), the membranes were 174 incubated overnight at 4°C with the primary antibodies (Table 1) . After washing the membrane, 175 incubation with HRP-conjugated secondary antibody was performed at room temperature for 1 hour. 176
WesternBright Quantum HRP substrate (Advansta, Menlo Park, CA, USA) was added to the membranes 177 to capture the luminescent signal using the Proxima 2850 Imager (IsoGen Life Sciences, De Meern, The 178 Netherlands). Equal loading of samples was verified by primary monoclonal mouse anti-GAPDH 179 antibodies (clone GAPDH-71.1, Sigma-Aldrich, Belgium). 180
In vivo PM-PDX-derived cell line model and animal study 181
Female 4-week-old SCID/Beige (C.B-17/IcrHsd-Prkdc scid Lyst bg-J ) mice (Envigo, The Netherlands) were 182 treated daily via oral gavage with vehicle (0.5% methylcellulose and 0.2% Tween 80 in water, n = 6) or 183 trametinib (0.3 mg/kg/day, n = 6). Mice were treated starting 1 week after intraperitoneal injection of 184 1×10^6 Luciferase-EGFP expressing PM-PDX-derived cells (1:1 serum free EMEM medium:Matrigel 185 (Corning, The Netherlands)). After 5 weeks of oral treatment, mice were sacrificed. Tumour 186 development was assessed by weekly bioluminescence imaging until six weeks after cell injection. In 187 order to measure bioluminescent signals, mice were given an intraperitoneal injection of 100 µL 188
Xenolight D-luciferin (K+ Salt, Perkin Elmer, Belgium) in DPBS (without Ca 2+ and Mg 2+ , 150 mg/kg 189 mouse) and were anaesthetized with isoflurane (5% in oxygen for induction and 1.5% in oxygen for 190 maintenance, IsoFlo, Abbott, Belgium). Imaging was initiated 15 minutes after injection using the IVIS 191 Lumina II (Caliper Life Sciences). Exposure times were set automatically. 192
Statistical analysis 193
Results obtained with the colony formation assay were analysed using one-way ANOVA with Tukey's 194 multiple comparisons test using Graphpad Prism 7 (GraphPad Software, USA). Using R Studio (17), 195
Mann-Whitney U test was used to compare differences in relative total flux between groups in the in 196 Figure 1D ). 213
Characterization of tumor-derived cell lines 214
Primary culture from single cell suspension of patient-derived peritoneal metastasis resulted in spread-215 polarized cells that typically showed signs of senescence characterized by a larger surface area and 216 stress fibers (Figure 2A) . These cultures showed a mixed expression of cytoskeletal proteins alfa-217 smooth muscle actin and cytokeratin and cell-cell adhesion molecules epithelial (E-) and neural (N-) 218 cadherin, and most likely can be considered as mixed mesothelial-fibroblast cultures. In contrast, 219 primary culture starting from tissue of the first passage PM-PDX model resulted in typical epithelial 220 cells with cobblestone organization with strong cell-cell adhesion that showed colony growth. The first 221 5 to 8 initial subcultures showed no constant timing (among 2 to 3 weeks), the period in which cell 222 proliferation was slow and unable to cover the entire culture flask surface. After this period, cell 223 proliferation became quicker and in vitro passages for the maintenance of cell culture became regular 224 (every week). The cell culture, named as PM-LGSOC-01, has been in continuous culture for >30 months 225 and >100 in vitro passages (Figure 2A ). PM-LGSOC-01 cells had a doubling time of 42 hours at passage 226 5 that was reduced to 23 hours at passage 22 and later passages. Table 2 summarizes Figure 3A . Due to the presence of this mutation, the efficacy of the MEK inhibitors 240 trametinib and selumetinib was further investigated. Indeed, trametinib dose-dependently inhibits 241 ERK phosphorylation and cell confluency with an IC50 of 7.2 ± 0.5 nM (mean ± SE) ( Figure 3B ). 242 Selumetinib also affected cell confluency but only in higher molar concentrations. In agreement with 243 the poor chemosensitivity of LGSOC only paclitaxel shows a sensitivity in the low nM range (IC50 of 6.3 244 ± 2.2 nM (mean ± SE)) in contrast to platinum based compounds with IC50 > 2 µM ( Figure 3C ). In 245 agreement, the clonogenic assay confirmed the effect of trametinib and selumetinib on clone numbers 246 ( Figure 3C ). Cell cycle analysis confirmed the impact of trametinib on cellular growth by stimulating a 247 cell population into an increased G1 phase and decreased S and G2/M phase ( Figure 3D) . 248 249
Impact of trametinib in an in vivo peritoneal metastasis model of LGSOC 250
PM-LGSOC-01 cells were lentiviral transduced to obtain constitutive GFP-and Luciferase expression. 251
These reporter cells were further used to create a peritoneal metastasis model from LGSOC in order 252 to evaluate the effect of trametinib in vivo. Figure 4A illustrates the imaging data at different time 253 points before and during the treatment period. In both groups, during the time course of the 254 experiment no mice developed ascites. Animals received daily oral gavage based on vehicle or 255 0.3 mg/kg trametinib in a volume of 100 µL. Over time a clear increase in bioluminescence activity 256 can be observed for the control group whereas a decrease in signal is observed in the trametinib 257 treatment group. After 5 weeks of treatment animals were euthanised and relative total flux was 258 significantly higher in the control group compared to the trametinib group ( Figure 4B) . On average 259 a 4-fold increase in bioluminescent increase from the start of the experiments was observed for the 260 control group whereas on average the bioluminescent signal decreased with about 30% in the 261 trametinib group, relative to starting conditions. Figure 4C illustrates the histopathological (H&E) and 262 immunohistochemical stainings (Ki67 and PAX8) representative for both the control and trametinib 263 group. H&E shows nests of cells that organize into papillae surrounded by stroma characteristic of 264
LGSOC. Ki67 labeling index was twice as high in the control group (30%) compared to the trametinib 265 group (15%). 266 267
Discussion
268
The heterogeneous nature of ovarian cancer makes it challenging to predict therapeutic responses in 269 patients (18, 19) . In this regard, preclinical models accurately mimicking biological properties of in vivo 270 human tumors are of great value for efficient drug discovery (20). To date, preclinical research in 271
LGSOC has been limited. The low frequency and slow growth rate of these tumors have challenged the 272 development of cell lines and animal xenograft models.
LGSOC cell lines are not available at the 273 American Type Culture Collection (ATCC) and are only available at some research groups worldwide 274 (21, 22) . Kopper et al. (2019) established organoid lines in basement membrane extracts representing 275 both LGSOC and HGSOC from primary tumor, ascites and peritoneal metastasis (11). The organoid lines 276 allow subcutaneous transplantation and can be used in drug screening assays. Our approach was 277 slightly different. A tumor slurry from peritoneal metastatic tissue of LGSOC was subperitoneally 278 injected into an immunodeficient SCID/Beige mouse leading to tumor growth. From this early-stage 279 PDX a tissue-culture substrate adherent cell line was established that showed long term in vitro 280 expansion and enabled manipulation and functional analysis. We also confirmed the histological 281 features of the early-stage PDX such as micropapillae surrounded by stroma in the first passage and 282 marked architectural complexity in the second passage most probably due to anastomosis of 283 micropapillae forming the elongated and branching structures. The genomic aberration characterized 284 by KRAS mutation is consistent in the PM-PDX and PM-LGSOC-01 cell line. Biomarker expression, such 285 as positive PAX8 and WT1 combined with a wildtype p53 is consistent in the primary tissue versus the 286 PM-PDX and PM-LGSOC-01, even after extended passage. Ovarian PDXs are predominantly originating 287 from HGSOC as a low take rate and long latency is often associated with other histological subtypes. 288
However, in our case HGSOC patients were strongly pretreated by chemotherapy and characterized 289 by necrotic areas and areas containing cancer cells with low mitotic activity making it less likely to 290 establish a PDX model from PM of HGSOC patients. In contrast, the LGSOC patient did not receive 291 neoadjuvant chemotherapy before surgery leading to more viable tumor tissue, easily forming an 292 early-stage transplantable PDX and generated tissue-culture adherent PM-LGSOC-01 cell line, low sensitive to platinum derivatives. Other characteristics are clonogenicity and tumorigenicity, lack of 294 serum-induced chemotactic migration and absence of compact sphere forming activity despite the 295 presence of cell-cell adhesion molecule E-cadherin and its downstream catenins. PM-LGSOC-01 cell 296 line allows genetic manipulation and easy in vivo monitoring of its luc-EGFP variant using 297 bioluminescence imaging. The mouse passaging of PM tumor tissue was necessary to obtain a tissue-298 culture adherent cell line since cells cultured directly from patient PM tumor tissue ended into 299 dominant growth of stromal cells such as fibroblasts and mesothelial cells that become senescent after 300 further passaging. 301
Prior studies have reported that LGSOC tumors have a unique clinical, pathological and molecular 302 profile compared to other ovarian cancers.
LGSOC harbours KRAS mutations in 19 to 54.5% of the cases 303 and lacks TP53 mutations (23-28). With the focus on inhibiting KRAS signalling via downstream effector 304 MEK, both allosterically active compounds trametinib and selumetinib were here investigated (29). 305
Trametinib shows equal potency for targeting MEK1 and MEK2 and preferentially binds 306 unphosphorylated MEK1/2 and thereby preventing Raf-dependent MEK phosphorylation and 307 activation (30, 31) . Selumetinib targets the unique inhibitor binding pocket adjacent to the Mg-ATP in 308 MEK1/2. Sticking to this specific region causes a conformational change in unphosphorylated MEK1/2 309 resulting in a catalytically inactive position and blocking MEK1/2 from accessing the ERK1/2 activation 310 loop. Selumetinib does not block binding and phosphorylation by Raf, which is different from 311 trametinib (32). In addition, selumetinib shows higher potency to target MEK1 compared to MEK2. 312
These different binding properties of selumetinib compared to trametinib result in higher IC50 for 313 selumetinib in MEK sensitive tumors (reported IC50 values of 50 nM for trametinib and 2.5 µM for 314 selumetinib using the A549 bronchioloalveolar carcinoma cell monolayer cultures (33)) which is in 315 agreement with work done by Gilmartin et al. (30) and Yamaguchi et al. (34) . The study of Fernandez 316 et al. (35) marks differences in MEK efficacy in low-grade serous ovarian cancer cell lines as trametinib 317 was found to be highly effective in blocking p-ERK1/2 compared to selumetinib (IC50 values were in 318 the nM range for trametinib versus the µM-range for selumetinib). These findings are also in line with 319 our observations regarding a different sensitivity for both MEK inhibitors with the established PM-320
LGSOC-01 cells. In vivo evaluation of trametinib in PM-LGSOC-01 revealed a similar sensitivity 321 suggesting that the peritoneal stroma does not affect the trametinib response. Due to the failure of 322 MEK inhibitors such as binimetinib in a phase 3 clinical trial for LGSOC and the unknown molecular 323 mechanisms related to this failure (8), we strongly believe that the current model will assist in the 324 better understanding of responsiveness and resistance to MEK inhibitors. 325
Establishing and analysing additional LGSOC lines might substantiate our finding and may provide a 326 unique opportunity to study LGSOC progression and chemosensitivity. 327
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